Top ▲
Target id: 1886
Nomenclature: BAFF receptor
Abbreviated Name: BAFF-R
Systematic Nomenclature: TNFRSF13C
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 184 | 22q13.2 | TNFRSF13C | TNF receptor superfamily member 13C | |
Mouse | 1 | 175 | 15 E1 | Tnfrsf13c | tumor necrosis factor receptor superfamily, member 13c | |
Rat | - | - | Tnfrsf13c | TNF receptor superfamily member 13C |
Database Links | |
Alphafold | Q96RJ3 (Hs), Q9D8D0 (Mm) |
ChEMBL Target | CHEMBL4630882 (Hs) |
Ensembl Gene | ENSG00000159958 (Hs), ENSMUSG00000068105 (Mm), ENSRNOG00000007664 (Rn) |
Entrez Gene | 115650 (Hs), 72049 (Mm), 500910 (Rn) |
Human Protein Atlas | ENSG00000159958 (Hs) |
KEGG Gene | hsa:115650 (Hs), mmu:72049 (Mm), rno:500910 (Rn) |
OMIM | 606269 (Hs) |
Pharos | Q96RJ3 (Hs) |
UniProtKB | Q96RJ3 (Hs), Q9D8D0 (Mm) |
Wikipedia | TNFRSF13C (Hs) |
Natural/Endogenous Ligands |
BAFF {Sp: Human} |
Adaptor proteins (Human) |
TRAF3 |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
This is a type III membrane bound receptor for B cell activating factor (BAFF). BAFF enhances B cell survival and hence regulates the peripheral B cell population. It is suggested that overproduction of BAFF may enhance the survival of autoreactive B cells, an effect which may contribute in the pathogenesis of autoimmune diseases. The anti-BAFF receptor monoclonal antibody ianalumab (VAY736; Novartis) has progressed to clinical evaluation in autoimmune conditions and B cell malignancies. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
Immuno Disease Associations | ||||||||||
|
||||||||||
|
||||||||||
|
1. Heusser C, Neugebauer J, Schaadt E, Urlinger S, Woisetschlaeger M. (2010) Compositions and methods of use for therapeutic antibodies. Patent number: WO2010007082A1. Assignee: Novartis. Priority date: 17/07/2008. Publication date: 21/01/2010.
2. Rahmanzadeh R, Weber MS, Brück W, Navardi S, Sahraian MA. (2018) B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurol Scand, 137 (6): 544-556. [PMID:29512131]